Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ERN1 | O75460 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11929032 | 0.87 | TSHR (0.47) | LMNATSHRALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL13664107 | 0.82 | LMNA (0.62) | LMNATSHRPOLBALDH1A1KDM4E | |
| SCHEMBL13664699 | 0.80 | ALDH1A1 (0.44) | LMNATSHRALDH1A1KDM4ECYP1A2 | |
| SCHEMBL10969853 | 0.80 | LMNA (0.68) | LMNATSHRPOLBALDH1A1KDM4E | |
| SCHEMBL10773535 | 0.79 | LMNA (0.53) | LMNATSHRPOLBALDH1A1KDM4E | |
| SCHEMBL38660114 | 0.79 | ALDH1A1 (0.58) | LMNATSHRPOLBALDH1A1KDM4E | |
| SCHEMBL11929037 | 0.77 | TSHR (0.41) | LMNATSHRPOLBALDH1A1KDM4E | |
| SCHEMBL6901917 | 0.76 | LMNA (0.50) | LMNATSHRPOLBALDH1A1KDM4E | |
| SCHEMBL3431542 | 0.76 | LMNA (0.69) | LMNATSHRPOLBALDH1A1KDM4E | |
| SCHEMBL1654627 | 0.76 | LMNA (0.49) | LMNATSHRPOLBALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090270614-A1 | OPTICALLY ACTIVE QUATERNARY AMMONIUM SALT HAVING AXIAL ASYMMETRY AND PROCESS FOR PRODUCING ALPHA-AMINO ACID AND DERIVATIVE THEREOF WITH THE SAME | NAGASE & CO., LTD. (JP) | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270614-A1 | OPTICALLY ACTIVE QUATERNARY AMMONIUM SALT HAVING AXIAL ASYMMETRY AND PROCESS FOR PRODUCING ALPHA-AMINO ACID AND DERIVATIVE THEREOF WITH THE SAME | BCAT1, BCAT2, AADAT | LMNA 4073/4885TSHR 3260/4885POLB 476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.